# Phase 2 Myeloproliferative Disorders trials: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials in phase 2 for Myeloproliferative Disorders that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Myeloproliferative Disorders trials: 33 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/myeloproliferative-disorders

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946289 | Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment | University Hospital, Brest | Phase 2 | Not yet recruiting | Myeloproliferative Neoplasm | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946289) |
| October 23, 2026 | NCT07891533 | Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera | AN2 Therapeutics, Inc | Phase 2 | Not yet recruiting | Polycythemia Vera (SNOMED CT: 109992005) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891533) |
| June 9, 2026 | NCT07634536 | Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant | Stanford University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634536) |
| June 4, 2026 | NCT07626021 | Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | Zhongshan Hospital (Xiamen), Fudan University | Phase 2 | Not yet recruiting | Myeloproliferative Neoplasms | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626021) |
| May 7, 2026 | NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572929) |
| April 14, 2026 | NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) | University of Manitoba | Phase 2 | Not yet recruiting | Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET), Acute Myeloid Leukemia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528417) |
| March 13, 2026 | NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic... | Jonsson Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468916) |
| March 24, 2025 | NCT06892223 | Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation | Istituto Clinico Humanitas | Phase 2 | Recruiting | Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892223) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| February 7, 2025 | NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815003) |
| October 28, 2024 | NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | National Cancer Institute (NCI) | Phase 2 | Recruiting | Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06661915) |
| September 19, 2024 | NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | University of Manitoba | Phase 2 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06599762) |
| August 1, 2024 | NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen | St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532084) |
| June 27, 2024 | NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06477549) |
| March 18, 2024 | NCT06315309 | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | University of Alabama at Birmingham | Phase 2 | Recruiting | GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315309) |
| February 20, 2024 | NCT06265584 | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant | University of Alabama at Birmingham | Phase 2 | Recruiting | Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06265584) |
| September 28, 2023 | NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1... | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06059391) |
| August 28, 2023 | NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06013423) |
| April 10, 2023 | NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia... | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05805605) |
| March 29, 2023 | NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | Karolinska University Hospital | Phase 2 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia With Myelodysplasia Related Disease and \< 30% Blasts, Mixed... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05788679) |
| October 3, 2022 | NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05564390) |
| September 26, 2022 | NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute... | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05554406) |
| August 30, 2022 | NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Myeloproliferative Neoplasm, Acute Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05521204) |
| October 12, 2021 | NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | University Health Network, Toronto | Phase 2 | Recruiting | Myeloproliferative Neoplasm | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05074355) |
| August 9, 2021 | NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Cogent Biosciences, Inc. | Phase 2 | Recruiting | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL)... | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04996875) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 3 |
| Masonic Cancer Center, University of Minnesota | 2 |
| City of Hope Medical Center | 2 |
| University of Alabama at Birmingham | 2 |
| University of Manitoba | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| Fred Hutchinson Cancer Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| Jonsson Comprehensive Cancer Center | 1 |
| Cogent Biosciences, Inc. | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Karolinska University Hospital | 1 |
| Stanford University | 1 |
| Zhongshan Hospital (Xiamen), Fudan University | 1 |
| Institut Paoli-Calmettes | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Istituto Clinico Humanitas | 1 |
| University of Liege | 1 |
| University Health Network, Toronto | 1 |
| Medical College of Wisconsin | 1 |
| University of Washington | 1 |
| University Hospital, Brest | 1 |
| AN2 Therapeutics, Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| Canada | 6 |
| Puerto Rico | 2 |
| Australia | 2 |
| Belgium | 2 |
| France | 2 |
| Italy | 2 |
| Russia | 2 |
| Austria | 1 |
| Germany | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Poland | 1 |
| Spain | 1 |
| Switzerland | 1 |
| United Kingdom | 1 |
| Sweden | 1 |
| China | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Wind energy companies in the United States](https://specstream.ai/data/businesses/wind-energy-companies/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Ultrasound imaging clinics in the United States](https://specstream.ai/data/businesses/ultrasound-imaging-clinics/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
